Studies for the application of boron neutron capture therapy to the treatment of differentiated thyroid cancer

Applied Radiation and Isotopes

Volumn 69, Issue 12, 2011, Pages 1752-1755

  Dagrosa, A ^a,b   Carpano, M ^a   Perona, M ^a,b   Thomasz, L ^a   Nievas, S ^a   Cabrini, R ^a   Juvenal, G ^a,b   Pisarev, M ^a,b,c  

^a DEPARTAMENTO DE FÍSICA   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^c Department of Biochemistry   (Argentina)

Author keywords

BPA; Differentiated; Thyroid cancer; Uptake

Indexed keywords

BIODISTRIBUTIONS; BORON NEUTRON CAPTURE THERAPY; BPA; CELL LINES; DIFFERENTIATED; DIFFERENTIATED THYROID CANCER; DIFFERENTIATED THYROID CARCINOMAS; IN-VITRO; INTRACELLULAR CONCENTRATION; NUDE MICE; THYROID CANCERS; UPTAKE;

BORON; BORON COMPOUNDS; CELL CULTURE; DISEASES; DOSIMETRY; MAMMALS;

PATIENT TREATMENT;

4 BORONOPHENYLALANINE B 10; IODINE 131;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL LEVEL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SELECTIVITY; DRUG TUMOR LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IODINE 131 UPTAKE TEST; MOUSE; NEUTRON CAPTURE THERAPY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RAT; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TISSUE DISTRIBUTION; TUMOR DIFFERENTIATION;

ANIMALS; BORON COMPOUNDS; BORON NEUTRON CAPTURE THERAPY; CELL DIFFERENTIATION; CELL LINE, TUMOR; HUMANS; MICE; MICE, NUDE; PHENYLALANINE; THYROID NEOPLASMS;

EID: 80055079545     PISSN: 09698043     EISSN: 18729800     Source Type: Journal    
DOI: 10.1016/j.apradiso.2011.02.030     Document Type: Article

References (17)

1. Aihara T., Hiratsuka J., Morita N., Uno M., Sakurai Y., Maruhashi A., Ono K., Harada T. First clinical case of boron neutron capture therapy for head and neck malignancies using 18F-BPA PET. Head Neck. 2006, 28(9):850-855.
2. Are C., Shaha A.R. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann. Surg. Oncol. 2006, 13:453-464.
3. Coderre J.A., Morris G.M. The radiation biology of boron neutron capture therapy. Radiat. Res. 1999, 151:1-18.
4. Coderre J.A., Chanana A.D., Joel D.D., Elowitz E.H., Micca P.L., Nawrocky M.M., Chadha M., Gebbers J.O., Shady M., Peress N.S., Slatkin D.N. Biodistribution of borophenylalanine in patients with glioblastoma multiforme: boron concentration correlates with tumor cellularity. Radiat. Res. 1998, 149:163-170.
5. Dagrosa M.A., Viaggi M.E., Kreimann E., Farias S., Garavaglia R., Agote M., Cabrini R., Dadino J., Juvenal G., Pisarev M. Selective uptake of p-borophenylalanine by undifferentiated thyroid carcinoma for boron neutron capture therapy. Thyroid 2002, 12:7-12.
6. Dagrosa M.A., Viaggi M., Longhino J., Calzetta O., Cabrini R., Edreira M., Juvenal G., Pisarev M. Experimental application of boron neutron capture therapy (BNCT) to undifferentiated thyroid carcinoma (UTC). Int. J. of Radiat. Oncol. Biol. Phys. 2003, 57(4):1084-1092.
7. Dagrosa M.A., Thomasz L., Longhino J., Perona M., Calzetta O., Blaumann H., Jiménez Rebagliati R., Cabrini R.L., Kahl S.B., Juvenal G.J., Pisarev M.A. Optimization of the application of boron neutron capture therapy (BNCT) to the treatment of undifferentiated thyroid cancer (UTC). Int. J. of Radiat. Oncol. Biol. Phys. 2007, 69(4):1059-1066.
8. Gilliland F.D., Hunt W.C., Morris D.M., Key C.R. Prognostic factors for thyroid carcinoma: a population-based study of 15,698 cases from the surveillance, epidemiology and end results (SEER) program 1973-1991. Cancer 1997, 79:564-573.
9. Kato, I., Ono, K., Sakurai, Y., Ohmae, M., Kamida, A., Fujita, Y., et al., 2006. Boron neutron capture therapy for recurrent head and neck malignancies. In: Nakagawa Y., Kobayashi T., Fukuda H. (Eds). Proceedings of ICNCT-12. Kagawa, Japan, pp. 1-4.
10. Kato I., Ono K., Sakurai Y., Ohmae M., Maruhashi A., Imahori Y., Kirihata M., Nakazawa M., Yura Y. Effectiveness of BNCT for recurrent head and neck malignancies. Appl Radiat. Isot. 2004, 61(5):1069-1073.
11. Lee Y.-S., Bulliard D.E., Zalutsky M.R. Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131 I-radiolabeled murine monoclonal antibody in a human glioma xenograft model. Cancer Res. 1988, 48:559-565.
12. Liberman S.J., Dagrosa A., Jiménez Rebagliati R.A., Bonomi M.R., Roth B.M., Turjanski L., Castiglia S.I., González S.J., Menéndez P.R., Cabrini R., Roberti M.J., Batistoni D.A. Biodistribution studies of boronophenylalanine-fructose in melanoma and brain tumor patients in Argentina. Appl. Radiat. Isot. 2004, 61(5):1095-1100.
13. Lowry O.H., Roseborough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J Biol. Chem. 1951, 193:265-275.
14. Mishima Y., Imahori Y., Honda C., Hiratsuka J., Ueda S., Ido T. In vivo diagnosis of human melanoma with positron emission tomography using specific melanoma-seeking 18F-DOPA analogue. J. Neurooncol. 1997, 33:163-169.
15. Pisarev M., Dagrosa M.A., Juvenal G. Application of boron neutron capture therapy to the treatment of anaplasic thyroid carcinoma: current status and future perspectives. Curr. Opinion Endocrinol. Diabetes 2005, 12:352-355.
16. Wittig A., Sauerwein W.A., Coderre J.A. Mechanisms of transport of p-borono-phenylalanine trough the cell membrane in vitro. Radiat. Res. 2000, 153:173-180.
17. Yamamoto T., Nakai K., Matsumura A. Boron neutron capture therapy for glioblastoma. Cancer Lett. 2008, 262(2):143-152.